SCHEMBL4354553

SCHEMBL4354553

O=[N+]([O-])c1ccc(Sc2ccc(Cl)cc2)c(CNc2cccc(F)c2O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
MAPT P10636 5/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
PDE7A Q13946 6/20 0.41
HTT P42858 1/20 0.40
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
PDE7B Q9NP56 3/20 0.39
RORC P51449 1/20 0.39
IDO1 P14902 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4D Q08499 1/20 0.38
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4342595 0.90 TBXA2R (0.44) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4347132 0.90 MAPT (0.43) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4346428 0.90 MAPT (0.47) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4351108 0.89 NPC1 (0.42) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4341851 0.88 MAPT (0.46) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4356033 0.87 NPC1 (0.49) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4344193 0.87 NPC1 (0.41) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4346831 0.87 KMT2A (0.49) NPC1MAPTMEN1KMT2AGAA
SCHEMBL4350125 0.86 MEN1 (0.43) MAPTMEN1KMT2AGAAPKM
SCHEMBL4351298 0.85 MAPT (0.44) NPC1MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 NPC1 815/4885MAPT 4439/4885MEN1 2168/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 NPC1 1189/4885MAPT 4184/4885MEN1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.